Indication: Non-Small Cell Lung Cancer (NSCLC)

MAINTENANCE SYSTEMIC THERAPY VERSUS CONSOLIDATIVE STEREOTACTIC BODY RADIATION THERAPY (SBRT) PLUS MAINTENANCE SYSTEMIC THERAPY FOR LIMITED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE II/III TRIAL

Limited Metastatic

Sub-indication: limited metastatic NSCLC, no PD-L1 expression & 3 or less sites, patient consented at end of 4 cycles of chemo

Line of Therapy: Maintenance systemic therapy versus SBRT + Maintenance systemic therapy after 4 cycles of upfront chemo

Drug Study

Principal Investigator: Yong Cha, M.D.
Norton Cancer Institute

Sponsor: NRG Oncology

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.